Juno hammered on new ROCKET deaths

Juno Therapeutics Inc. (NASDAQ:JUNO) placed a voluntary clinical hold on the Phase II ROCKET trial of JCAR015 to treat acute lymphoblastic leukemia following two new deaths in patients with cerebral edema. Juno has now reported five deaths in ROCKET.

Its shares plummeted $7.31 (24%) to $22.57 on Wednesday, hitting an intraday low of $19.41 and marking its first trading below $20 since the company priced its IPO at $24 in December 2014...